Saudi FDA Licensing Director Hajed Hashan On CTD And Drug Licensing: An Interview With PharmAsia News
This article was originally published in PharmAsia News
Executive Summary
As licensing director of the Saudi Food and Drug Administration, Dr. Hajed Hashan plays a key role in the largest pharmaceutical market in the Gulf region and one of the largest in the Middle East. Established in 2004, SFDA has recently initiated several changes aimed at standardizing its filing and registration process and making SFDA the leading regional health regulator. Along the sidelines of the Drug Information Association's Middle East Regulatory Conference in Amman, Jordan, Hashan spoke to PharmAsia News about some of SFDA's newest initiatives, regulatory challenges and the pharmaceutical environment in the kingdom.
You may also be interested in...
Amgen Middle East Regulatory Affairs Director Adel Djalal On Drug Pricing And Regulatory Environment - An Interview With PharmAsia News (Part 2 of 2)
Amgen is targeting the Middle East as a new growth area, and it plans to venture further into Gulf countries, from Saudi Arabia and war-torn Iraq to countries like Algeria and Libya.
Jordanian FDA Drug Director Laila Jarrar On Collaborations With Korean Regulators To Spur Biologics Growth - An Interview With PharmAsia News
The fast-growing pharmaceutical market in the Middle East has seen an increasing demand for regulators to step up to new challenges such as biologics and biosimilars, and to answer the call they are enhancing collaborations with leading health authorities around the world.
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).